DP-b99 is an investigational drug.
There have been 3 clinical trials for DP-b99.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Stroke, Ischemia, and Brain Ischemia. The leading clinical trial sponsors are D-Pharm Ltd. and [disabled in preview].